Home | CSACI

Prevention of Peanut Allergy - intro to babies

Join Us At The 75th Annual CSACI Scientific Virtual Meeting

October 22-24, 2020
The CSACI Annual Scientific Meeting (ASM) is a highly anticipated event each year and is our Society’s flagship event.
Learn More

Frequently Asked Questions about the New Infant Feeding Guidelines

The CSACI and Food Allergy Canada have put together a list for FAQ's in response to the New Peanut Introduction Guidelines. Thanks to everyone who participated, especially Drs. Kyla Hildebrand and Elissa Abrams. Download PDF

Addendum Guidelines for the Prevention of Peanut Allergy

"The “take home” messages include that peanut should be introduced early in the first year of life, and for the majority of infants, peanut can be introduced at home. The only group of infants for which medical assessment is recommended is those with severe eczema, egg allergy or both."Read On...

Top 5 Reasons to Choose Allergy & Immunology as Your Specialty

Canada is in the midst of the “Allergy Epidemic”. Up to 40% of the Canadian population will be affected by at least one allergic condition in some point of their lives, and the prevalence of certain atopic conditions,Read More

Passionate About The Nose and Sinuses in the Practice of Allergy and Clinical Immunology?

We already have regular core of section members and are actively looking for new members who are interested.Read More

ACCESS OUR COVID-19 RESOURCES »

CSACI Position Statement

Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria Read more »

Read the AACI JOURNAL »

CHOISIR AVEC SOIN »

Hot Topics

Canadian Dermatology Association and Canadian Society of Allergy and Clinical Immunology Issue Joint Statement Against the Canadian Agency for Drugs and Technologies in Health Recommendation (PDF) »

L’Association canadienne de dermatologie et la Société canadienne d’allergie et d’immunologie clinique diffusent une déclaration commune contre la recommandation de l’Agence canadienne des médicaments et des technologies de la santé (PDF) »